Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Apr 24;15(9):2428.
doi: 10.3390/cancers15092428.

Irreversible Electroporation for Liver Metastases from Colorectal Cancer: A Systematic Review

Harry V M Spiers  1   2 , Francesco Lancellotti  3 , Nicola de Liguori Carino  3 , Sanjay Pandanaboyana  4 , Adam E Frampton  5   6 , Santhalingam Jegatheeswaran  3 , Vinotha Nadarajah  7 , Ajith K Siriwardena  3
Affiliations
Review

Irreversible Electroporation for Liver Metastases from Colorectal Cancer: A Systematic Review

Harry V M Spiers et al. Cancers (Basel). .

Abstract

Background: Irreversible electroporation (IRE) is a non-thermal form of ablation based on the delivery of pulsed electrical fields. It has been used to treat liver lesions, particularly those in proximity to major hepatic vasculature. The role of this technique in the portfolio of treatments for colorectal hepatic metastases has not been clearly defined. This study undertakes a systematic review of IRE for treatment of colorectal hepatic metastases.

Methods: The study protocol was registered with the PROSPERO register of systematic reviews (CRD42022332866) and reports in compliance with the preferred reporting items for systematic reviews and meta-analyses (PRISMA). The Ovid MEDLINE®, EMBASE, Web of Science and Cochrane databases were queried in April 2022. The search terms 'irreversible electroporation', 'colon cancer', 'rectum cancer' and 'liver metastases' were used in combinations. Studies were included if they provided information on the use of IRE for patients with colorectal hepatic metastases and reported procedure and disease-specific outcomes. The searches returned 647 unique articles and the exclusions left a total of eight articles. These were assessed for bias using the methodological index for nonrandomized studies (MINORS criteria) and reported using the synthesis without meta-analysis guideline (SWiM).

Results: One hundred eighty patients underwent treatment for liver metastases from colorectal cancer. The median transverse diameter of tumours treated by IRE was <3 cm. Ninety-four (52%) tumours were adjacent to major hepatic inflow/outflow structures or the vena cava. IRE was undertaken under general anaesthesia with cardiac cycle synchronisation and with the use of either CT or ultrasound for lesion localisation. Probe spacing was less than 3.2 cm for all ablations. There were two (1.1%) procedure-related deaths in 180 patients. There was one (0.5%) post-operative haemorrhage requiring laparotomy, one (0.5%) bile leak, five (2.8%) post-procedure biliary strictures and a zero incidence of post-IRE liver failure.

Conclusions: This systematic review shows that IRE for colorectal liver metastases can be accomplished with low procedure-related morbidity and mortality. Further prospective study is required to assess the role of IRE in the portfolio of treatments for patients with liver metastases from colorectal cancer.

Keywords: ablation; colorectal cancer; irreversible electroporation; liver metastases; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
PRISMA Flowchart.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. [(accessed on 23 April 2022)]. Available online: https://ecis.jrc.ec.europa.eu/pdf/Colorectal_cancer_factsheet-Mar_2021.pdf.
    1. Siriwardena A.K., Mason J.M., Mullamitha S., Hancock H.C., Jegatheeswaran S. Management of colorectal cancer presenting with synchronous liver metastases. Nat. Rev. Clin. Oncol. 2014;11:446–459. doi: 10.1038/nrclinonc.2014.90. - DOI - PubMed
    1. Cervantes A., Adam R., Roselló S., Arnold D., Normanno N., Taïeb J., Seligmann J., De Baere T., Osterlund P., Yoshino T., et al. ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann. Oncol. 2023;34:10–32. doi: 10.1016/j.annonc.2022.10.003. - DOI - PubMed
    1. [(accessed on 25 January 2023)]. Available online: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
    1. Ruers T., Punt C., Van Coevorden F., Pierie J., Borel-Rinkes I., Ledermann J., Poston G., Bechstein W., Lentz M., Mauer M., et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: A randomized EORTC Intergroup phase II study (EORTC 40004) Ann. Oncol. 2012;23:2619–2626. doi: 10.1093/annonc/mds053. - DOI - PMC - PubMed

LinkOut - more resources